Use of Bivalirudin for Chronic Total Occlusion Percutaneous Intervention: Insights From the PROGRESS-CTO Registry

CONCLUSION: Bivalirudin is infrequently used during retrograde CTO-PCI. While the incidence of adverse events was similar with unfractionated heparin, larger studies are needed to assess the safety of bivalirudin.PMID:36821841

Source: The Journal of Invasive Cardiology - February 23, 2023 Category: Cardiology Authors: Louis Verreault-Julien Bahadir Simsek Spyridon Kostantinis Athanasios Rempakos Judit Karacsonyi Taral N Patel Brian K Jefferson Mitul Patel Paul B Poommipanit Barry F Uretsky Khaldoon Alaswad Sevket Gorgulu Omer Goktekin Jaikirshan Khatri Dmitrii Khelimsk Source Type: research